Please assess the completion status of the following clinical trial:

Trial Title: PGD2 Formation in Vascular Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with existing CAD admitted for elective PTCA:~  1. Treated with any dose of aspirin daily for at least 5 days, with special interest in those treated with 81 mg aspirin daily or~ 2. Treated with an alternative antiplatelet therapy, such as clopidogrel, due to aspirin hypersensitivity or PMDs preference or~ 3. No aspirin therapy at all~* Patients presenting to the ER with Acute Coronary Syndrome(ACS)who will have a PTCA~* Patients with stable angina or positive stress tests scheduled for a cardiac catheterization~Exclusion Criteria:~* History of unstable diabetes (hgb A1c\>8 or FBS\> 200)~* Uncontrolled hypertension (SBP \> 180, DBP \>100)~* History of an acute confounding disease as judged on clinical screen that according to the investigator may interfere with interpretation of the study results, or compromise the safety of a potential subject.~* Patients who have taken NSAIDS or COX-2 inhibitors other than aspirin, for at least 10 days prior to PTCA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- No Aspirin Treatment (Type: None): None
- 81 mg Aspirin Treatment (Type: None): None
- 325 mg Aspirin (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).